Valmark Advisers Inc. Takes $576,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Valmark Advisers Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, Holdings Channel reports. The fund acquired 7,300 shares of the company’s stock, valued at approximately $576,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Truist Financial Corp lifted its holdings in TransMedics Group by 60.7% during the 4th quarter. Truist Financial Corp now owns 12,462 shares of the company’s stock valued at $984,000 after purchasing an additional 4,707 shares during the last quarter. Sandhill Capital Partners LLC lifted its holdings in TransMedics Group by 4.2% during the 4th quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after purchasing an additional 30,591 shares during the last quarter. Atria Wealth Solutions Inc. bought a new position in TransMedics Group during the 4th quarter valued at about $415,000. New York State Common Retirement Fund lifted its holdings in TransMedics Group by 41.9% during the 4th quarter. New York State Common Retirement Fund now owns 87,516 shares of the company’s stock valued at $6,908,000 after purchasing an additional 25,849 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of TransMedics Group by 44.0% in the fourth quarter. Handelsbanken Fonder AB now owns 7,200 shares of the company’s stock worth $568,000 after acquiring an additional 2,200 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 117,078 shares of company stock worth $9,972,971. 7.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Oppenheimer boosted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. Piper Sandler assumed coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.00.

TransMedics Group Stock Up 3.2 %

Shares of NASDAQ:TMDX opened at $92.08 on Monday. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63. The company has a 50 day moving average of $82.98 and a 200-day moving average of $74.89. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -119.58 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 158.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) earnings per share. On average, sell-side analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.